People with polyendocrine metabolic ovarian syndrome (PMOS) should have their condition diagnosed sooner and be offered an annual review to monitor symptoms, treatment and long-term health risks, ...

A new treatment option is now available on the NHS for cervical cancer that has come back or spread to other parts of the body, following our final draft guidance published today.

Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer TA1167 18 June 2026 18 June 2026 ...

Browse guidance by topic Cancer Biliary tract cancers Bladder cancer Blood and bone marrow cancers Brain cancers Breast cancer Cervical cancer Colorectal cancer Complications of cancer Endometrial ...

Adults with acute ST-segment-elevation myocardial infarction (STEMI) who present within 12 hours of onset of symptoms have primary percutaneous coronary intervention (PCI), as the preferred coronary ...

Teplizumab is the disease-modifying therapy for type 1 diabetes and England is the first country in Europe to recommend it's use through a health technology appraisal.

NICE’s healthtech guidance provided me with the perfect catalyst for change.

This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or ...

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] ...

Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.

This guideline has been updated and replaced by the NICE guideline on overweight and obesity management (NG246) ...

Our guidance takes many forms: NICE guidelines (clinical, social care, public health, medicines practice), technology appraisals, interventional procedures, medical technologies, diagnostics and ...